Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAFV600 mutation-positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study

被引：23
|
作者：
Dreno, Brigitte
Ascierto, Paolo Antonio
McArthur, Grant A.
Atkinson, Victoria
Liszkay, Gabriella
Di Giacomo, Anna Maria
Mandala, Mario
Demidov, Lev V.
Stroyakovskiy, Daniil
Thomas, Luc
De la Cruz-Merino, Luis
Dutriaux, Caroline
Garbe, Claus
Rooney, Isabelle Anne
Hsu, Jessie J.
Park, Erica
Ribas, Antoni
Larkin, James M. G.
机构：
[1] CHU Nantes, Dept Dermatol, Nantes, France
[2] Natl Tumour Inst Fdn G Pascal, Naples, Italy
[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[4] Univ Melbourne, Melbourne, Vic, Australia
[5] Univ Queensland, Brisbane, Qld, Australia
[6] Natl Inst Oncol, Budapest, Hungary
[7] Univ Hosp Siena, Ctr Immuno Oncol, Siena, Italy
[8] Papa Giovanni XXIII Canc Ctr Hosp, Bergamo, Italy
[9] N N Blokhin Russian Canc Res Ctr, Moscow, Russia
[10] Moscow City Oncol Hosp 62, Moscow, Russia
[11] Lyon Univ, Cancerol Inst Lyon Civ Hosp, Canc Res Ctr Lyon, Pierre Benite, France
[12] Hosp Univ Virgen Macarena, Seville, Spain
[13] Bordeaux Hosp, Dermatol & Pediat Dermatol Dept, Bordeaux, France
[14] Eberhard Karls Univ Tubingen, Tubingen, Germany
[15] Genentech Inc, San Francisco, CA USA
[16] Univ Calif Los Angeles, Los Angeles, CA USA
[17] Jonsson Comprehens Canc Ctr, Los Angeles, CA USA
[18] Royal Marsden Hosp, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.9522
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9522
引用
收藏
页数：2
相关论文
共 27 条
  • [1] 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study
    Ascierto, Paolo A.
    Dreno, Brigitte
    Larkin, James
    Ribas, Antoni
    Liszkay, Gabriella
    Maio, Michele
    Mandala, Mario
    Demidov, Lev
    Stroyakovskiy, Daniil
    Thomas, Luc
    de la Cruz-Merino, Luis
    Atkinson, Victoria
    Dutriaux, Caroline
    Garbe, Claus
    Hsu, Jessie
    Jones, Surai
    Li, Haocheng
    McKenna, Edward
    Voulgari, Athina
    McArthur, Grant A.
    CLINICAL CANCER RESEARCH, 2021, 27 (19) : 5225 - 5235
  • [2] Open-label, multicenter safety study of vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma
    Larkin, James M. G.
    Del Vecchio, Michele
    Ascierto, Paolo Antonio
    Schachter, Jacob
    Garbe, Claus
    Neyns, Bart
    Mandala, Mario
    Lorigan, Paul
    Miller, Wilson H.
    Guminski, Alexander David
    Berking, Carola
    Rutkowski, Piotr
    Queirolo, Paola
    Hauschild, Axel
    Arance, Ana Maria
    Brown, Michael Paul
    Mitchell, Lada
    Veronese, Maria Luisa
    Blank, Christian U.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Safety and Efficacy of Vemurafenib in Patients with BRAFV600 Mutation-Positive Metastatic Melanoma Previously Treated with Ipilimumab: a Subgroup Analysis from a Vemurafenib Expanded Access Program
    Hamid, O.
    Flaherty, L.
    Day, B. -M
    Abhyankar, S.
    Hainsworth, J.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 : 54 - 55
  • [4] Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAFV600 mutation-positive melanoma with central nervous system (CNS) metastases (mets): Primary results from phase 2 Tricotel study.
    Dummer, Reinhard
    Queirolo, Paola
    Guijarro, Ana Maria Abajo
    Hu, Youyou
    Wang, Dao
    Azevedo, Sergio Jobim
    Robert, Caroline
    Ascierto, Paolo Antonio
    Chiarion-Sileni, Vanna
    Pronzato, Paolo
    Spagnolo, Francesco
    Mujika, Karmele
    Liszkay, Gabriella
    Merino, Luis De la Cruz
    Tawbi, Hussein A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
    McArthur, Grant A.
    Chapman, Paul B.
    Robert, Caroline
    Larkin, James
    Haanen, John B.
    Dummer, Reinhard
    Ribas, Antoni
    Hogg, David
    Hamid, Omid
    Ascierto, Paolo A.
    Garbe, Claus
    Testori, Alessandro
    Maio, Michele
    Lorigan, Paul
    Lebbe, Celeste
    Jouary, Thomas
    Schadendorf, Dirk
    O'Day, Stephen J.
    Kirkwood, John M.
    Eggermont, Alexander M.
    Dreno, Brigitte
    Sosman, Jefferey A.
    Flaherty, Keith T.
    Yin, Ming
    Caro, Ivor
    Cheng, Suzanne
    Trunzer, Kerstin
    Hauschild, Axel
    LANCET ONCOLOGY, 2014, 15 (03): : 323 - 332
  • [6] Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAFV600 mutation-positive melanoma with central nervous system (CNS) metastases (mets): Final results and exploratory biomarker analysis from the phase 2 TRICOTEL study
    Dummer, Reinhard
    Levesque, Mitchell
    Bellini, Elisa
    Chen, Marissa
    Hu, Youyou
    Wong, Tiffany
    Stassen, Katja
    Duhard, Pauline
    Yan, Yibing
    Tawbi, Hussein A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis
    Blank, Christian U.
    Larkin, James
    Arance, Ana M.
    Hauschild, Axel
    Queirolo, Paola
    Del Vecchio, Michele
    Ascierto, Paolo A.
    Krajsova, Ivana
    Schachter, Jacob
    Neyns, Bart
    Garbe, Claus
    Sileni, Vanna Chiarion
    Mandala, Mario
    Gogas, Helen
    Espinosa, Enrique
    Hospers, Geke A. P.
    Miller, Wilson H., Jr.
    Robson, Susan
    Makrutzki, Martina
    Antic, Vladan
    Brown, Michael P.
    EUROPEAN JOURNAL OF CANCER, 2017, 79 : 176 - 184
  • [8] Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients with BRAFV600 mutation-positive advanced melanoma: Primary results from the phase 3 IMspire150 trial
    McArthur, A.
    Stroyakovskiy, Daniil
    Gogas, Helen
    Robert, Caroline
    Lewis, Karl
    Protsenko, Svetlana
    Pereira, Rodrigo
    Eigentler, Thomas
    Rutkowski, Piotr
    Demidov, Lev
    Manikhas, Georgy Moiseevich
    Yan, Yibing
    Huang, K. C.
    Uyei, Anne
    McNally, Virgina
    Gutzmer, Ralf
    Ascierto, Paolo
    CANCER RESEARCH, 2020, 80 (16)
  • [9] Vemurafenib in Chinese patients with BRAFV600 mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study
    Si, Lu
    Zhang, Xiaoshi
    Xu, Zhen
    Jiang, Qiudi
    Bu, Lilian
    Wang, Xuan
    Mao, Lili
    Zhang, Weijiang
    Richie, Nicole
    Guo, Jun
    BMC CANCER, 2018, 18
  • [10] Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
    Chapman, P. B.
    Robert, C.
    Larkin, J.
    Haanen, J. B.
    Ribas, A.
    Hogg, D.
    Hamid, O.
    Ascierto, P. A.
    Testori, A.
    Lorigan, P. C.
    Dummer, R.
    Sosman, J. A.
    Flaherty, K. T.
    Chang, I.
    Coleman, S.
    Caro, I.
    Hauschild, A.
    McArthur, G. A.
    ANNALS OF ONCOLOGY, 2017, 28 (10) : 2581 - 2587
123